Industry Overview - The cholesterol-lowering drug industry is crucial for preventing and treating cardiovascular diseases, with a growing patient population due to aging and increasing rates of dyslipidemia [1][8] - The prevalence of dyslipidemia among the elderly is high, with 47% of individuals over 60 affected, while the rate among those aged 18 and above has risen from 18.6% in 2002 to 35.6% in 2023 [8][10] Market Development - The cholesterol-lowering drug market in China is projected to grow from CNY 252.94 billion in 2023 to CNY 265.95 billion in 2024, despite a slowdown due to national procurement policies [10][20] - Sales distribution shows that 57% of sales come from hospitals, while 43% are from retail markets [10] Drug Categories - Cholesterol-lowering drugs are categorized into statins, fibrates, niacin, bile acid sequestrants, PCSK9 inhibitors, and monoclonal antibodies targeting angiopoietin-like protein 3 [3][12] - Statins dominate the market with a 76.58% share, but innovative drugs like PCSK9 inhibitors are gaining traction [12][22] Competitive Landscape - The market is experiencing significant changes, with foreign companies like Pfizer and Sanofi leading the high-end market, while local firms like Yuyuan Health and Jingxin Pharmaceutical focus on mid to low-end markets [14][16] - Competition is shifting from price to efficacy, safety, and brand service, with an expected increase in market concentration through mergers and international collaborations [14][22] Company Highlights - Jingxin Pharmaceutical focuses on the development and sales of statins and is expanding into combination therapies and new drug targets [16] - Yuyuan Health has developed a PCSK9-targeting siRNA drug, YKYY015, which is in clinical trials and has received IND approval in the U.S. [18] - The revenue of Yuyuan Health is projected to decline by 9.9% in 2024, with cardiovascular drug sales down by 20.73% [18] Future Trends - The market for cholesterol-lowering drugs is expected to continue expanding due to an increasing patient population and unmet treatment needs, with projections indicating a compound annual growth rate above a certain percentage [20][21] - Innovation in drug development is on the rise, with companies investing in new targets like Lp(a) and PCSK9 inhibitors, enhancing treatment options for patients [21][22]

Group 1: Research and Development - The company has 4 specialized pharmaceutical research institutions and 1 postdoctoral workstation, with a research team of approximately 200 people, accounting for about 20% of total employees. In 2024, R&D investment is expected to be 16.76% of sales revenue [1] - The WYY project is a novel compound with over 20 intellectual property applications globally, demonstrating superior efficacy and safety compared to competitors in animal studies. It is currently in the preclinical research stage, with an IND application planned for submission within the year [2] Group 2: Project Updates - The Wuhan Psychological Rehabilitation Hospital project received its medical institution practice license by the end of December 2024, aiming to operate as a tertiary specialized hospital [4] - The company is advancing the production line for recombinant collagen, with stable production processes meeting industry standards, and is preparing for large-scale production [6] Group 3: Market and Financial Insights - The gross profit margin for the company's main product, "A Le," has remained around 60% despite the impact of centralized procurement policies [8] - The company is considering external licensing for the WYY project based on clinical trial progress and commercialization conditions [3] Group 4: Future Developments - The company is focusing on developing CBD for treating pulmonary arterial hypertension, with a significant unmet market demand, as there are approximately 12 million patients in China [7][8] - VGX-3100, a key project of a major associate company, is undergoing phase III clinical trials for HPV-related cervical lesions, with plans to complete participant enrollment by 2025 [8]

证券代码：000813 证券简称：德展健康 公告编号：2025-033 德展大健康股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 关于公司诉讼事项的进展公告 特别提示： 1、案件所处的诉讼阶段：原告不服一审裁定，提起上诉 2、公司所处的当事人地位：被告 3、对上市公司损益产生的影响：本案件尚未开庭审理，暂无法判断对公司 本期利润或期后利润的影响。 一、本次诉讼基本情况 因德展大健康股份有限公司（以下简称"公司"、"德展健康"）原控股股 东美林控股集团有限公司的关联方天宝嘉麟国际贸易有限公司与北京华新盛融 信息咨询有限公司（以下简称"北京华新"）之间合同纠纷，北京华新向北京市 第三中级人民法院（以下简称"北京三中院"）提起诉讼。 公司于 2025 年 3 月 25 日收到了北京三中院发来的（2022）京 03 民初 382 号《民事裁定书》，获悉北京三中院难以认定北京华新在本案中所主张的诉讼权 利和利益符合民事诉讼法第一百二十二条规定的原告是与本案有直接利害关系 的公民、法人和其他组织。依据相关法律法规，北京三中院裁定驳回北京华新的 起诉。有关上述 ...

关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036）。2025 年 1 月 23 日，公司披露了《关于增加回购股份资金来源的公告》（公告编号：2025- ...

Core Viewpoint - The announcement details the completion of the transfer of shares held by a major shareholder, Shanghai Yueye, following a court-ordered auction, and outlines the upcoming fifth auction of remaining shares [3][4][10]. Group 1: Share Auction Details - Shanghai Yueye's shares were auctioned based on a liquidation plan confirmed by the Shanghai Third Intermediate People's Court [3]. - The fourth auction resulted in the successful transfer of 65,088,066 shares, which is 3.01% of the company's total share capital, while 323,800,000 shares remain for the fifth auction [4][6]. - The fifth auction is scheduled from May 15, 2025, to May 16, 2025, with a minimum bidding quantity reduced from 1 million shares to 500,000 shares [7][8]. Group 2: Shareholder Information - As of the announcement date, Shanghai Yueye has cumulatively auctioned 90,338,066 shares, representing 4.17% of the company's total share capital [10]. - The shares auctioned are classified as unrestricted tradable shares, although they are subject to certain selling restrictions [6][10]. - Shanghai Yueye is not the controlling shareholder, and the auction of its shares will not affect the company's control or normal operations [13]. Group 3: Compliance and Regulatory Information - The auction process complies with relevant laws and regulations, including the Securities Law and the Shenzhen Stock Exchange's self-regulatory guidelines [12]. - The company will continue to monitor the auction process and fulfill its information disclosure obligations as required [13].

证券代码：000813 证券简称：德展健康 公告编号：2025-031 德展大健康股份有限公司 公司于近日收到公司持股 5%以上股东上海岳野清算组出具的《股票拍卖过 户告知函》及《告知函》，获悉其在第四次拍卖股份中被竞拍成功的公司 65,088,066 股股份已于近日办理完成过户登记手续。同时，上海岳野清算组已 在京东司法拍卖平台再次发布了拍卖公告，定于 2025 年 5 月 15 日 10 时至 2025 年 5 月 16 日 10 时 止 （ 延 时 除 外 ） 在 京 东 司 法 拍 卖 平 台 （https://paimai.jd.com/308410399）对其所持 323,800,000 股公司股份进行 第五次公开拍卖。现将有关情况公告如下： 一、第四次拍卖股份过户情况 关于持股 5%以上股东所持公司股份拍卖过户完成 及第五次拍卖的提示性公告 股东上海岳野股权投资管理合伙企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、上海岳野股权投资管理合伙企业（有限合伙）（以下 ...

德展大健康股份有限公司 简式权益变动报告书 上市公司名称：德展大健康股份有限公司 股票上市地点：深圳证券交易所 股票简称：德展健康 股票代码：000813 信息披露义务人：上海岳野股权投资管理合伙企业（有限合伙） 住所：北京市朝阳区嘉泰国际大厦A座1705 通讯地址：北京市朝阳区嘉泰国际大厦A座1705 股份变动性质：股份减少、被动稀释 签署日期：2025年4月30日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办法》 《深圳证券交易所股票上市规则》《公开发行证券的公司信息披露内容与格式准则 第15号——权益变动报告书》等相关的法律、法规和规范性文件编制本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《深圳证券交易所 股票上市规则》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报 告书》的规定，本报告书已全面披露了信息披露义务人在德展大健康股份有限公司中拥 有权益的股份变动情况。 四、截至本报告书签署之日 ...

Core Viewpoint - 德展健康's Q1 2025 financial report shows a decline in revenue and net profit, indicating challenges in the current market environment [1][3] Financial Performance - The company's total revenue for Q1 2025 was 89.28 million yuan, ranking 131 among peers, a decrease of 11.82% year-on-year [1] - The net profit attributable to shareholders was -22.11 million yuan, ranking 136 among peers, a decline of 530.98 thousand yuan compared to the same period last year [1] - Operating cash flow was 18.04 million yuan, ranking 80 among peers, down 20.60% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 4.11%, ranking 2 among peers, an increase of 1.20 percentage points from the previous quarter and 1.30 percentage points from the same period last year [3] - The gross profit margin is 59.82%, ranking 54 among peers, a decrease of 4.31 percentage points from the previous quarter but an increase of 8.25 percentage points year-on-year [3] - Return on equity (ROE) is -0.43%, ranking 125 among peers, a decrease of 0.11 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.01 yuan, ranking 122 among peers, remaining stable compared to the same period last year [3] - The total asset turnover ratio is 0.02 times, ranking 150 among peers, unchanged from the previous year but down 11.64% year-on-year [3] - The inventory turnover ratio is 0.18 times, ranking 144 among peers, a decrease of 0.06 times compared to the previous year, down 26.78% year-on-year [3] Shareholder Structure - The number of shareholders is 65,400, with the top ten shareholders holding 1.201 billion shares, accounting for 55.46% of the total share capital [3] - The largest shareholder is 上海岳野股权投资管理合伙企业(有限合伙) with a holding of 19.13% [3]

Core Viewpoint - The company is in a transformation phase but is increasing R&D investment, with several innovative drugs making progress, which provides assurance for future revenue growth [1][2]. Financial Performance - In 2024, the company achieved revenue of 466 million yuan, with a net loss attributable to shareholders of 20.41 million yuan, resulting in a basic earnings per share of -0.0095 yuan [1]. - For Q1 2025, the company reported revenue of 89.28 million yuan and a net loss attributable to shareholders of 22.11 million yuan [1]. - The gross profit margin improved to 64.13% in 2024, an increase of 5.39 percentage points from the previous year, primarily due to significant reductions in labor and manufacturing costs [1]. - As of the end of 2024, total assets were 5.319 billion yuan, with total liabilities of 154 million yuan, mostly interest-free; equity attributable to shareholders was 5.158 billion yuan, and the debt-to-asset ratio remained low at 2.91% [1]. R&D Investment - The company increased R&D investment to 78.20 million yuan in 2024, a year-on-year growth of 53.05%, with R&D expenses accounting for 16.76% of revenue, up 6.50 percentage points from the previous year [1]. - In 2024, the company was granted 11 invention patents and filed 43 patent applications, indicating strong R&D activity [1]. Innovative Drug Projects - The WYY innovative drug project has completed laboratory research and is progressing in pharmacology and toxicology, with expectations to obtain clinical trial permits in both China and the U.S. by the end of 2025 [3]. - The company has initiated production line construction for the semaglutide project and completed pilot tests for recombinant human collagen [3]. - Progress has been made in CBD-related projects, including preclinical studies for a new drug for pulmonary arterial hypertension and the establishment of a pharmaceutical-grade CBD raw material workshop [3]. Other Key Projects - The company’s associate, Dongfang Lue Biotechnology, is advancing the VGX-3100 project, which is in Phase III clinical trials for treating cervical precancerous lesions caused by HPV [4]. - Other key projects are ongoing, including the ZT project, which is optimizing lead compounds, and a flavonoid compound project for pancreatic cancer [4]. Future Strategy - In 2025, the company plans to leverage industry policy benefits, strengthen existing product lines, enhance innovation capabilities, and promote the industrialization of research outcomes [5]. - The company aims to establish a new ecosystem in the pharmaceutical and health industry, focusing on a "pharmaceutical + medical + health" business model [5].

目 录 关于德展大健康股份有限公司 2024 年度营业收入 扣除事项的专项核查意见 中兴财光华审专字（2025）第 226019 号 关于德展大健康股份有限公司 2024 年度营业 收入扣除事项的专项核查意见 德展大健康股份有限公司 2024 年度营业收入 扣除情况表 关于德展大健康股份有限公司 2024 年度营业收入 扣除事项的专项核查意见 中兴财光华审专字（2025）第 226019 号 德展大健康股份有限公司： 我们接受委托，对德展大健康股份有限公司（以下简称德展健康）2024 年度财务报表进行审计，并出具了中兴财光华审会字（2025）第 226019 号审 计报告。在此基础上，我们对德展健康编制的《德展大健康股份有限公司 2024 年度营业收入扣除情况表》（以下简称"营业收入扣除情况表"）进行 了核查。 一、管理层的责任 德展健康管理层负责按照《深圳证券交易所股票上市规则（2024 年修 订）》和《深圳证券交易所上市公司自律监管指南第 1 号——业务办理（2024 年修订）》的规定编制营业收入扣除情况表，并设计、执行和维护必要的内 部控制，以使营业收入扣除情况表不存在由于舞弊或错误导致的重大错报。 二 ...